HLB Therapeutics Co.,Ltd.
115450
株式のランク
#18248
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
株価
$2.02
時価総額
$190.66M
変化（1日）
7.96%
変化（1年）
-1.16%
国
KR
取引 HLB Therapeutics Co.,Ltd. (115450)
カテゴリー
Healthcare
HLB Therapeutics Co.,Ltd.（115450）の株価履歴
終値の最高値: $1.94 （2026-10-01）
終値の最安値: $9.82 （2010-03-01）
終値の最安値: $9.82 （2010-03-01）
HLB Therapeutics Co.,Ltd. の株価履歴（2010 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -4.53% |
| 2025 | -69.48% |
| 2024 | 142.67% |
| 2023 | -24.36% |
| 2022 | -34.28% |
| 2021 | -50.71% |
| 2020 | 1.61% |
| 2019 | 7.70% |
| 2018 | -17.13% |
| 2017 | 106.04% |
| 2016 | 24.88% |
| 2015 | 254.54% |
| 2014 | 20.37% |
| 2013 | -14.85% |
| 2012 | -28.46% |
| 2011 | -62.15% |
| 2010 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $536.13 | 25.72% |
US
|
|
| $200.12 | 645.31% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $880.01 | 8.09% |
NL
|
